Accuray Incorporated

NasdaqGS ARAY

Accuray Incorporated Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending December 31, 2024: USD 1.40 M

Accuray Incorporated Net Cash Used Provided By Financing Activities is USD 1.40 M for the Trailing 12 Months (TTM) ending December 31, 2024, a 137.02% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Accuray Incorporated Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending December 31, 2023 was USD -3.78 M, a -298.21% change year over year.
  • Accuray Incorporated Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending December 31, 2022 was USD -949.00 K, a 97.06% change year over year.
  • Accuray Incorporated Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending December 31, 2021 was USD -32.29 M, a -347.82% change year over year.
  • Accuray Incorporated Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending December 31, 2020 was USD -7.21 M, a -115.86% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
NasdaqGS: ARAY

Accuray Incorporated

CEO Ms. Suzanne Winter M.B.A.
IPO Date Feb. 8, 2007
Location United States
Headquarters 1240 Deming Way
Employees 987
Sector Healthcare
Industries
Description

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Similar companies

FNA

Paragon 28, Inc.

USD 13.00

-0.08%

ANIK

Anika Therapeutics, Inc.

USD 17.79

-1.00%

OFIX

Orthofix Medical Inc.

USD 18.47

-2.99%

NPCE

NeuroPace, Inc.

USD 13.66

-4.41%

SGHT

Sight Sciences, Inc.

USD 2.71

-5.58%

AXGN

AxoGen, Inc.

USD 18.33

-2.91%

SRDX

Surmodics, Inc.

USD 34.06

0.62%

TELA

TELA Bio, Inc.

USD 2.76

-1.43%

AORT

Artivion, Inc.

USD 31.27

-1.36%

BVS

Bioventus Inc.

USD 10.84

-1.90%

SIBN

SI-BONE, Inc.

USD 17.28

-4.53%

AVNS

Avanos Medical, Inc.

USD 16.99

-1.62%

APYX

Apyx Medical Corporation

USD 1.39

-6.08%

KIDS

OrthoPediatrics Corp.

USD 23.71

-3.85%

CTSO

Cytosorbents Corporation

USD 1.05

3.96%

CLPT

ClearPoint Neuro, Inc.

USD 18.90

0.53%

StockViz Staff

February 7, 2025

Any question? Send us an email